Key Technology, a US manufacturer of process automation systems, has promoted Bret Larreau to the new position of manager of business development. He takes responsibility for building new business alliances and developing acquisition opportunities that will expand Key’s solutions within the pharmaceutical and food manufacturing industries.
Larreau has been with Key Technology for eight years and brings 25 years of automated food processing equipment experience to his position. Prior to this promotion, he was the product marketing manager responsible for Key’s optical sorters.
Before joining Key, he was a senior project manager for Integrated Packaging Systems and prior to that, he worked in engineering, manufacturing management, sales support management and product management for DSI/Stein, part of FMC FoodTech.
‘It’s exciting to make this shift, leveraging my experience in the industry and recent market development activities, to focus on finding new opportunities to improve customers’ operations and grow Key’s business,’ said Larreau.
‘We’ve the resources and the personnel to make new partnerships, acquisitions, and licensing a high priority, while continuing to work closely with existing partners on ongoing projects.’
Key Technology makes a promotion
Bret Larreau becomes manager of business development
You may also like
Manufacturing
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Design & Build
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics
The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility
The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics
The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite
The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale